# C. Michael Gibson

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/c-michael-gibson/

## Facts

| Field | Value |
| --- | --- |
| Citations | 64,727 |
| Field | Acute Myocardial Infarction Research |
| h-index | 113 |
| i10-index | 455 |
| Last Known Institution | Baim Institute for Clinical Research |
| OpenAlex ID | https://openalex.org/A5007026783 |
| ORCID iD | https://orcid.org/0000-0002-4857-9125 |
| Works | 898 |

## Researcher papers

Showing 12 of 15.

- [Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes](https://scholariq.org/papers/prasugrel-versus-clopidogrel-in-patients-with-acute-coronary-syndromes/)
- [COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up](https://scholariq.org/papers/covid-19-and-thrombotic-or-thromboembolic-disease-implications-for-prevention/)
- [Addition of Clopidogrel to Aspirin and Fibrinolytic Therapy for Myocardial Infarction with ST-Segment Elevation](https://scholariq.org/papers/addition-of-clopidogrel-to-aspirin-and-fibrinolytic-therapy-for-myocardial/)
- [Rivaroxaban in Patients with a Recent Acute Coronary Syndrome](https://scholariq.org/papers/rivaroxaban-in-patients-with-a-recent-acute-coronary-syndrome/)
- [Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial](https://scholariq.org/papers/prasugrel-compared-with-clopidogrel-in-patients-undergoing-percutaneous-coronary/)
- [Prognostic Value of Quantitative Contrast-Enhanced Cardiovascular Magnetic Resonance for the Evaluation of Sudden Death Risk in Patients With Hypertrophic Cardiomyopathy](https://scholariq.org/papers/prognostic-value-of-quantitative-contrast-enhanced-cardiovascular-magnetic/)
- [Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention](https://scholariq.org/papers/defining-high-bleeding-risk-in-patients-undergoing-percutaneous-coronary-2/)
- [Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease](https://scholariq.org/papers/evacetrapib-and-cardiovascular-outcomes-in-high-risk-vascular-disease/)
- [2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials](https://scholariq.org/papers/2017-cardiovascular-and-stroke-endpoint-definitions-for-clinical-trials/)
- [Platelet Inhibition with Cangrelor in Patients Undergoing PCI](https://scholariq.org/papers/platelet-inhibition-with-cangrelor-in-patients-undergoing-pci/)
- [Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk](https://scholariq.org/papers/defining-high-bleeding-risk-in-patients-undergoing-percutaneous-coronary/)
- [Hospital Delays in Reperfusion for ST-Elevation Myocardial Infarction](https://scholariq.org/papers/hospital-delays-in-reperfusion-for-st-elevation-myocardial-infarction/)

## Researcher topics

- [Acute Myocardial Infarction Research](https://scholariq.org/topics/acute-myocardial-infarction-research/)
- [Coronary Interventions and Diagnostics](https://scholariq.org/topics/coronary-interventions-and-diagnostics/)
- [Antiplatelet Therapy and Cardiovascular Diseases](https://scholariq.org/topics/antiplatelet-therapy-and-cardiovascular-diseases/)
- [Cardiac Imaging and Diagnostics](https://scholariq.org/topics/cardiac-imaging-and-diagnostics/)
- [Atrial Fibrillation Management and Outcomes](https://scholariq.org/topics/atrial-fibrillation-management-and-outcomes/)

## Researcher university

- [Baim Institute for Clinical Research](https://scholariq.org/institutions/baim-institute-for-clinical-research/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.